Patients with relapsed or refractory mantle cell lymphoma (MCL) treated with Calquence (acalabrutinib) remained progression-free for a median of 22 months.... Dec 07
Zydus, today announced that it has received permission to initiate the Phase 1 clinical trial of ZYIL1, a novel oral small molecule NLRP3 inhibitor candidate.... Dec 07
We continue to be encouraged by the findings from this Phase 1/2 study, which now include durable factor VIII expression through one year of ... Dec 07
-Advertisements-